GlassScriptPhysician profile
Stephen P Kovacs
NPI 1467574186
$519,502.26
in general payments reported to CMS, 2019-2025
36 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $69K · 2021: $67K · 2022: $71K · 2023: $61K · 2024: $136K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $186K · Travel and Lodging: $51K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $185,551.09 |
| Travel and Lodging | $50,903.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,402.00 |
| Food and Beverage | $15,249.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $247,905.65 | 2023-2025 | Galaxy |
| Ethicon INC. | $193,438.70 | 2019-2024 | Monarch Platform |
| Ethicon Endo-Surgery INC. | $38,241.94 | 2022-2024 | Monarch Platform |
| Medical Device Business Services, INC. | $26,231.89 | 2022-2023 | Monarch Platform |
| Auris Health, INC. | $6,099.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,721.07 | 2022-2025 | Glassia |
| Galvanize Therapeutics, INC | $739.89 | 2023-2025 | Aliya System |
| Astrazeneca Pharmaceuticals LP | $392.50 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Body Vision Medical INC. | $336.35 | 2023-2024 | Lungvision |
| Philips North America LLC | $326.32 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy, (Bi2) Igt Systems Undivided |
| Boston Scientific Corporation | $243.59 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.44 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Broncus Medical | $177.07 | 2019 | |
| Pulmonx Corporation | $171.15 | 2022 | |
| Amgen INC. | $146.19 | 2022-2025 | Tezspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imbio INC. | $129.25 | 2023 | Imbio Lung Density Analysis |
| Resmed Corp | $127.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $122.75 | 2022-2024 | Dupixent |
| Genzyme Corporation | $122.44 | 2024-2025 | |
| Intuitive Surgical, INC. | $76.28 | 2022 | |
| Jazz Pharmaceuticals INC. | $66.16 | 2022-2024 | |
| Insmed, INC. | $61.65 | 2022-2024 | Arikayce |
| Baxter Healthcare | $44.91 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $39.27 | 2022-2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $38.55 | 2024-2025 | Nucala |
| Electromed, INC. | $36.57 | 2025 | Smartvest |
| Mylan Specialty L.P. | $30.57 | 2022-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $28.26 | 2022 | |
| Janssen Biotech, INC. | $28.07 | 2024 | Rybrevant |
| Avadel Cns Pharmaceuticals, LLC | $28.05 | 2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $24.57 | 2023 | |
| Harmony Biosciences LLC | $23.47 | 2023 | Wakix |
| 4dmedical USA INC | $21.90 | 2024 | Ct Lvas |
| Viatris Specialty LLC | $19.44 | 2025 | Yupelri |
| Healthmyne, INC. | $18.37 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.